[HTML][HTML] Novel targeted therapies and immunotherapy for advanced thyroid cancers
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
Novel targeted therapies and immunotherapy for advanced thyroid cancers
GE Naoum, M Morkos, B Kim… - Molecular cancer, 2018 - pubmed.ncbi.nlm.nih.gov
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15-20% of differentiated thyroid cancer (DTC) cases and most …
prognosis of this disease, 15-20% of differentiated thyroid cancer (DTC) cases and most …
Novel targeted therapies and immunotherapy for advanced thyroid cancers.
GE Naoum, M Morkos, B Kim, W Arafat - Molecular Cancer, 2018 - europepmc.org
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
Novel targeted therapies and immunotherapy for advanced thyroid cancers.
GE Naoum, M Morkos, B Kim, W Arafat - Molecular Cancer, 2018 - search.ebscohost.com
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
[引用][C] Novel targeted therapies and immunotherapy for advanced thyroid cancers
GE Naoum, M Morkos, B Kim, W Arafat - Molecular Cancer, 2018 - cir.nii.ac.jp
Novel targeted therapies and immunotherapy for advanced thyroid cancers
GE Naoum, M Morkos, B Kim, W Arafat - Molecular Cancer, 2018 - go.gale.com
Background For the past several decades thyroid cancer has been the most common
endocrine tumor, with a~ 5% increase in incidence each year in the USA [1, 2]. The vast …
endocrine tumor, with a~ 5% increase in incidence each year in the USA [1, 2]. The vast …
[HTML][HTML] Novel targeted therapies and immunotherapy for advanced thyroid cancers
GE Naoum, M Morkos, B Kim, W Arafat - Molecular Cancer, 2018 - ncbi.nlm.nih.gov
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
[HTML][HTML] Novel targeted therapies and immunotherapy for advanced thyroid cancers
GE Naoum, M Morkos, B Kim… - Molecular …, 2018 - molecular-cancer.biomedcentral …
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
Novel targeted therapies and immunotherapy for advanced thyroid cancers
GE Naoum, M Morkos, B Kim, W Arafat - Molecular Cancer, 2018 - dash.harvard.edu
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
[PDF][PDF] Novel targeted therapies and immunotherapy for advanced thyroid cancers
GE Naoum, M Morkos, B Kim, W Arafat - 2018 - molecular-cancer.biomedcentral …
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …